Shimmer Research, provider of wearable wireless sensor products and solutions, and ClearSky Medical Diagnostics, a company that specializes in medical devices for the diagnosis and monitoring of neurodegenerative conditions, announced they are partnering to bring a new level of analytic capabilities to the use of wearable sensors in clinical research. This partnership will employ Shimmer’s Verisense wearable sensors platform with ClearSky algorithms and machine learning.
Verisense is a solution for reliably capturing accurate and complete biometric data. Worn on the wrist, the Verisense Inertial Measurement Unit (IMU) sensor can monitor activity and sleep. But Verisense can be used for any IMU application with up to seven sensors worn on different parts of a participant’s body, making it invaluable for studying complex musculoskeletal or neurological conditions, such as dystonia or epilepsy.
ClearSky Medical Diagnostics specializes in developing technologies for the diagnosis and monitoring of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions. Its clinically-validated medical devices have been used in medical centers worldwide and in clinical trials to demonstrate the efficacy of new drugs.
For more information, visit www.clearskymd.com or www.shimmersensing.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.